A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 532 participants.
Also called NCT01327183
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 532 participants
- Sponsor
- Registry
-
NCT01327183
-
- Other papers using this trial's data
- Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial
- Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, Netherlands, Poland
- Registry status
- Completed
Technical summary
Registry record NCT01327183. Randomized; double masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention
- Condition
- Myocardial Infarction
- Intervention (Procedure)
- Percutaneous Coronary Intervention (PCI (percutaneous coronary intervention))
- Intervention (Drug)
- RO4905417
- Intervention (Drug)
- RO4905417
- Intervention (Drug)
- placebo
- Lead sponsor
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct01327183- Content hash
c58f8860f92fe9fc2520e0bd07a710f0d8ebcd3a4f9ef6b5b3b1c2250f9c51d5